MEDU-33. PLK1 INHIBITION IN COMBINATION WITH STANDARD THERAPIES FOR MYC-DRIVEN MEDULLOBLASTOMA

In the recent past, polo-like kinase (PLK1) has gained considerable attention as a potential therapeutic target in medulloblastoma. Volasertib (BI6727), highly specific and potent PLK1 inhibitor, is under clinical trials. However, volasertib exhibits varied clinical efficacies and only few patients...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Balakrishnan, Ilango, Venkataraman, Sujatha, Pierce, Angela M, Alimova, Irina, Prince, Eric, Moreira, Daniel C., Fosmire, Susan, Madhavan, Krishna, Foreman, Nicholas, Vibhakar, Rajeev
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2017
Assuntos:
Abstracts
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5475157/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox083.183
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados